NCT05030077Unknown2 期
A Single-arm, Phase II Study of Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Tianjin Medical University Second Hospital1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2021年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial carcinoma.
详细描述
The primary objective is to determine the antitumor activity of anlotinib combined with platinum/gemcitabine (Objective Response rate, ORR) in patients with advanced urothelial carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75 years, ECOG PS: 0-
- •Unresectable or metastatic urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.
- •At least one measurable lesion according to RECIST 1.
- •The main organ function meets the following criteria within 7 days before enrollment:
- •Blood tests are subject to the following criteria (without blood transfusion within 14 days): hemoglobin (HB) ≥ 90g / L; neutrophil absolute value (ANC) ≥ 1.5 × 109 / L; platelets (PLT) ≥ 80 × 109 / L.
- •Biochemical tests are subject to the following criteria: total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5ULN, such as with liver metastasis, then ALT and AST ≤ 5ULN; serum creatinine (Cr) ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min.
- •Women of childbearing age must have taken reliable contraceptive measures and performed a pregnancy test (serum) within 3 days prior to enrollment, and the results were negative, and were willing to use appropriate methods during the trial and 180 days after the last administration of the test drug.
- •Patients voluntarily joined the study and signed informed consent, with good adherence and follow-up.
排除标准
- •Pregnant or lactating women.
- •A history of hypersensitivity to the study drugs.
- •Patients have received systemic treatment.
- •Patients with uncontrolled or high-load central nervous system metastases (or with obvious symptoms)
- •Patients with other diseases, including:
- •Hypertension and uncontrollable levels of normal anti-hypertensive medication: systolic blood pressure≥150 mmHg, diastolic blood pressure≥90 mmHg.
- •Unstable angina, newly diagnosed with angina or acute myocardial infarction within 6 months prior to enrollment, arrhythmia ( including: QTcF of male≥450ms ) requires medical intervention congestive heart failure (New York Heart Association (NYHA)≥2)
- •Active or uncontrollable infections (CTCAE 5.0≥2)
- •Known history of human immunodeficiency virus infection (HIV, congenital immune deficiency disease, or a history of organ transplantation)
- •Urinary protein ≥ ++ or 24 hours urine protein > 1 g
- •Any malignant tumor within 5 years, except those who have been cured or stabilized.
- •Uncured adverse events (NCI-CTCAE 5.0 grade II or greater) due to any treatment before, except for alopecia.
- •There are many factors that affect oral drug absorption (such as inability to swallow, Postgastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.).
- •Abnormal blood coagulation (PT>16s、APTT>43s、TT>21s、Fbg<2g/L), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy. Under the premise of an odds ratio (INR) ≤ 1.5, low-dose heparin (1mg daily) or low-dose aspirin (daily dose ≤ 100 mg) is allowed for preventive purposes.
- •Patients who underwent major surgical treatment, open biopsy, or significant traumatic injury within the first 4 weeks of enrollment.
- •Patients whose tumor has radiographically invaded an important vessel or whose tumor is determined by the investigators to be at high risk of incurring an important vessel and causing fatal hemorrhages during the study period.
- •Patients who have seizures and need treatment.
- •Patients with any signs of hemorrhage or history, regardless of severity; patients with any bleeding or bleeding episodes (NCI-CTCAE 5.0 grade III) within 4 weeks prior to grouping have unhealed wounds, ulcers, or fractures.
- •Artery or venous thrombosis occurred within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism.
- •Patients have been inoculated with attenuated live vaccine within 28 days before enrollment or plan to inoculate vaccine during the trial.
- •Other systemic diseases that can't be controlled (such as diabetes, etc.).
- •Patients with other serious physical or mental illness or laboratory abnormalities that may increase the risk of participating in the study or interfere with the results of the study, as well as patients that the investigator considers unfit to participate in the study.
- •Patients who have participated in clinical trials of other antitumor drugs within four weeks.
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: From date of enrollment until disease progression,assessed up to 1 year
The objective response rate is defined as the percentage of participants with measurable lesions achieving a Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria In Solid Tumors Version 1.1(RECIST v1.1) criteria. Per RECIST v1.1) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), greater than or equal to (\>=) 30 percent (%) decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
次要结局
- Duration of Response (DoR)(From date of enrollment until disease progression,assessed up to 3 years)
- Progression free survival (PFS)(From date of enrollment until the date of first documented progression,assessed up to 3 years)
- Overall Survival (OS)(From date of enrollment until death,assessed up to 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Anlotinib Maintenance Treatment for Advanced Soft Tissue SarcomaSoft Tissue SarcomaNCT03890068Sun Yat-sen University49
已完成
1 期
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung CancerNon-squamous Non-small-cell Lung CancerAnlotinibNCT04012619Sichuan University8
已完成
2 期
A Study of Anlotinib in Subjects With Advanced MalignancyAdvanced MalignancyNCT04216082Chia Tai Tianqing Pharmaceutical Group Co., Ltd.93
Unknown
3 期
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung CancerSmall Cell Lung CancerNCT04073550Chia Tai Tianqing Pharmaceutical Group Co., Ltd.184
Unknown
3 期
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung CancerSquamous Non-small Cell Lung CancerNCT04073537Chia Tai Tianqing Pharmaceutical Group Co., Ltd.386